TNSN07380A1 - [3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1 - Google Patents

[3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1

Info

Publication number
TNSN07380A1
TNSN07380A1 TNP2007000380A TNSN07380A TNSN07380A1 TN SN07380 A1 TNSN07380 A1 TN SN07380A1 TN P2007000380 A TNP2007000380 A TN P2007000380A TN SN07380 A TNSN07380 A TN SN07380A TN SN07380 A1 TNSN07380 A1 TN SN07380A1
Authority
TN
Tunisia
Prior art keywords
heteroarylamides
transport inhibitors
bicyclic
glycin
type
Prior art date
Application number
TNP2007000380A
Other languages
English (en)
Inventor
Stanton Furst Michardy
Iii John Adams Lowe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN07380A1 publication Critical patent/TNSN07380A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une série de [3.1.0] hétéroarylamides bicycliques substitués de formule I, dans laquelle les groupes A, Q, X, Y, Z et R1-R5 sont définis de la manière indiquée dans le présent mémoire, qui possèdent une activité‚ comme inhibiteurs du transport de glycine, leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques les contenant, leur utilisation pour améliorer la cognition et pour le traitement des symptômes positifs et négatifs de la schizophrénie et d'autres psychoses chez des mammifères, y compris les êtres humains.
TNP2007000380A 2005-04-08 2007-10-08 [3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1 TNSN07380A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66947205P 2005-04-08 2005-04-08
PCT/IB2006/000947 WO2006106425A1 (fr) 2005-04-08 2006-03-27 Heteroarylamides bicycliques [3.1.0 ] comme inhibiteurs de transport de la glycine

Publications (1)

Publication Number Publication Date
TNSN07380A1 true TNSN07380A1 (fr) 2009-03-17

Family

ID=36649611

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000380A TNSN07380A1 (fr) 2005-04-08 2007-10-08 [3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1

Country Status (31)

Country Link
US (2) US20060229455A1 (fr)
EP (1) EP1869019B1 (fr)
JP (1) JP4193949B2 (fr)
KR (1) KR100969402B1 (fr)
CN (1) CN101189228A (fr)
AP (1) AP2007004198A0 (fr)
AR (1) AR056307A1 (fr)
AU (1) AU2006231917B2 (fr)
BR (1) BRPI0608148A2 (fr)
CA (1) CA2603939C (fr)
CR (1) CR9493A (fr)
DK (1) DK1869019T3 (fr)
DO (1) DOP2006000078A (fr)
EA (1) EA014311B1 (fr)
ES (1) ES2520015T3 (fr)
GE (1) GEP20105053B (fr)
GT (1) GT200600136A (fr)
HN (1) HN2006013804A (fr)
IL (1) IL186409A (fr)
MA (1) MA29672B1 (fr)
MX (1) MX2007012463A (fr)
NL (1) NL1031539C2 (fr)
NO (1) NO339422B1 (fr)
NZ (1) NZ563238A (fr)
PE (1) PE20061400A1 (fr)
TN (1) TNSN07380A1 (fr)
TW (1) TW200719890A (fr)
UA (1) UA88518C2 (fr)
UY (1) UY29456A1 (fr)
WO (1) WO2006106425A1 (fr)
ZA (1) ZA200708481B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065500A2 (fr) * 2006-11-30 2008-06-05 Pfizer Products Inc. Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131957A2 (fr) 2008-04-21 2009-10-29 Institute For Oneworld Health Composés, compositions et traitements comprenant des dérivés d'oxydiazoles
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2010025890A1 (fr) * 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Dérivés de 3-azabicyclo[3.1.0]hexyle comme modulateurs des récepteurs métabotropiques du glutamate
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
EP2409976A4 (fr) * 2009-03-19 2012-09-19 Taisho Pharmaceutical Co Ltd Inhibiteur de transporteur de glycine
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AR077472A1 (es) * 2009-07-15 2011-08-31 Taisho Pharmaceutical Co Ltd Inhibidores de transportador de glicina
MX2012005258A (es) 2009-11-06 2012-06-19 Sk Biopharmaceuticals Co Ltd El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad.
AU2010316172B2 (en) 2009-11-06 2015-11-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
JP2013249257A (ja) * 2010-09-16 2013-12-12 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
JP2013249258A (ja) * 2010-09-17 2013-12-12 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
JPWO2012036278A1 (ja) 2010-09-17 2014-02-03 大正製薬株式会社 グリシントランスポーター阻害物質
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
ES2644758T3 (es) * 2012-10-16 2017-11-30 Tolero Pharmaceuticals, Inc. Moduladores de PKM2 y métodos para su uso
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
MA39888A (fr) 2014-04-24 2017-03-01 Dart Neuroscience Cayman Ltd Composés de 2,4,5,6-tétrahydropyrrolo[3,4-c] pyrazole et 4,5,6,7-tétrahydro-2 h-pyrazolo [4,3-c] pyridine utilisés comme inhibiteurs de glyt1
WO2016073420A1 (fr) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Composés azétidinyles substitués utilisés comme inhibiteurs de glyt1
AU2018378348A1 (en) 2017-12-05 2020-06-18 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
WO2019113079A1 (fr) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Mélanges non racémiques et leurs utilisations
CA3133460A1 (fr) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprenant des modulateurs de pkm2 et methodes de traitement les utilisant
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
CA3142355A1 (fr) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Formulations a liberation modifiee et utilisations associees
WO2021142329A1 (fr) * 2020-01-09 2021-07-15 Disc Medicine, Inc. Méthodes de traitement de protoporphyrie érythropoïétique, de protoporphyrie liée à x ou de porphyrie érythropoïétique congénitale avec des inhibiteurs de transport de glycine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322136A1 (fr) 1998-03-06 1999-09-10 Ludo Edmond Josephine Kennis Inhibiteurs du transport de la glycine
JP2002212179A (ja) 2001-01-15 2002-07-31 Wakunaga Pharmaceut Co Ltd 新規アニリド誘導体又はその塩及びこれを含有する医薬
CA2468761A1 (fr) 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Nouveaux composes anticancereux
FR2838739B1 (fr) 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005037216A2 (fr) * 2003-10-14 2005-04-28 Pfizer Products Inc. Derives [3.1.0] bicycliques utilises comme inhibiteurs des transporteurs de glycine
CN106434833A (zh) 2004-05-23 2017-02-22 杰勒德·M·豪斯 Theramutein调节剂

Also Published As

Publication number Publication date
MA29672B1 (fr) 2008-08-01
IL186409A0 (en) 2008-01-20
UY29456A1 (es) 2006-11-30
MX2007012463A (es) 2007-11-07
CA2603939C (fr) 2013-08-27
AU2006231917B2 (en) 2011-07-28
EA014311B1 (ru) 2010-10-29
TW200719890A (en) 2007-06-01
DOP2006000078A (es) 2006-10-15
CN101189228A (zh) 2008-05-28
DK1869019T3 (da) 2014-10-06
AR056307A1 (es) 2007-10-03
US8124639B2 (en) 2012-02-28
CR9493A (es) 2007-12-04
ZA200708481B (en) 2010-05-26
JP4193949B2 (ja) 2008-12-10
KR100969402B1 (ko) 2010-07-14
NZ563238A (en) 2011-01-28
EP1869019A1 (fr) 2007-12-26
US20100324020A1 (en) 2010-12-23
GEP20105053B (en) 2010-07-26
UA88518C2 (ru) 2009-10-26
CA2603939A1 (fr) 2006-10-12
KR20070120582A (ko) 2007-12-24
BRPI0608148A2 (pt) 2009-11-10
NO20074993L (no) 2007-11-02
NO339422B1 (no) 2016-12-12
EA200701902A1 (ru) 2008-04-28
AU2006231917A1 (en) 2006-10-12
AP2007004198A0 (en) 2007-10-31
WO2006106425A1 (fr) 2006-10-12
HN2006013804A (es) 2009-10-30
IL186409A (en) 2012-07-31
JP2008534671A (ja) 2008-08-28
NL1031539A1 (nl) 2006-10-10
PE20061400A1 (es) 2007-01-15
EP1869019B1 (fr) 2014-08-27
GT200600136A (es) 2006-11-07
ES2520015T3 (es) 2014-11-11
US20060229455A1 (en) 2006-10-12
NL1031539C2 (nl) 2007-04-10

Similar Documents

Publication Publication Date Title
TNSN07380A1 (fr) [3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1
MA28094A1 (fr) Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
TN2010000175A1 (fr) Piperidino-dihydrothienopyrimidines substituees
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA27438A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
ATE455777T1 (de) Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
MA31183B1 (fr) Inhibiteurs de mek
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
AP1860A (en) Aryl fused azapolycyclic compounds.
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
TW200634003A (en) Chemical compounds
ATE385238T1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
TNSN05250A1 (fr) Pyrimidinones substituees
MA27305A1 (fr) Derives de 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1